AZ enters agreement w/ Perrigo for Entocort in US

ASTRAZENECA ENTERS INTO AGREEMENT WITH PERRIGO FOR RIGHTS TO ENTOCORT® IN THE US



Divestment  further sharpens focus on three main therapy areas

Agreement follows ex-US divestment of Entocort in July 2015

AstraZeneca today announced that it has entered into an agreement with Perrigo
Company plc for the divestment of US rights to Entocort® (budesonide), a
gastroenterology medicine for patients with mild to moderate Crohn's disease, an
area of medicine outside AstraZeneca's strategic focus.

Under the terms of the agreement, Perrigo will pay AstraZeneca $380 million upon
completion of the transaction to acquire the rights to sell Entocort capsules
and the authorised generic Entocort capsules marketed by Par Pharmaceuticals.
The transaction does not include the transfer of any AstraZeneca employees or
facilities.

Luke Miels, Executive Vice President, Global Product and Portfolio Strategy,
AstraZeneca, said: "Our agreement with Perrigo completes the global divestment
of Entocort, emphasising our strategic focus on three main therapy areas and
providing further simplification of our supply chain. We are pleased to be
working with Perrigo to ensure patients with Crohn's disease in the US continue
to benefit from this important medicine."

Joseph C. Papa, Chairman, President and CEO, Perrigo, said: "The addition of
Entocort represents a strong strategic fit with our portfolio of prescription
medicines. It supports our commitment to providing effective, affordable
treatments to patients with gastroenterological conditions and we look forward
to building on the brand's success in the US market."

US product sales of Entocort were $89 million in the year-to-date (at nine
months 2015). The transaction is expected to complete by the end of 2015,
subject to customary closing conditions. AstraZeneca's 2015 Core Earnings Per
Share guidance was upgraded at Year-To-Date & Third Quarter 2015 Results on 5
November and is maintained as it was provided, in the range of mid to high
single-digit percentage increase versus the prior year and at constant exchange
rates. As AstraZeneca will no longer retain an interest in the US rights to
Entocort, the upfront gross receipt will be reported in Other Operating Income
in the Company's financial statements.

This agreement, along with the agreement (https://www.astrazeneca.com/our
-company/media-centre/press-releases/2015/astrazeneca-tillotts-pharma-entocort
-gastroenterology-medicine-17072015.html) entered into in July 2015 with
Tillotts Pharma AG, part of the Zeria Group, for the divestment of global rights
to Entocort outside the US, completes the global divestment of Entocort.

About Entocort

In capsule formulation, Entocort is a first-line therapy indicated for the
induction and maintenance of clinical remission of mild to moderate active
Crohn's disease involving the ileum and/or the ascending colon. As an enema,
Entocort is indicated for the induction and maintenance of clinical remission of
distal ulcerative colitis in the rectum, sigmoid colon and descending colon.

About Perrigo

Perrigo Company plc, a top five global over-the-counter (OTC) consumer goods and
pharmaceutical company, offers patients and customers high quality products at
affordable prices. From its beginnings in 1887 as a packager of generic home
remedies, Perrigo, headquartered in Ireland, has grown to become the world's
largest manufacturer of OTC products and supplier of infant formulas for the
store brand market. The Company is also a leading provider of generic extended
topical prescription products and receives royalties from Multiple Sclerosis
drug Tysabri®. Perrigo provides "Quality Affordable Healthcare Products®" across
a wide variety of product categories and geographies primarily in North
America, Europe, and Australia, as well as other markets,
including Israel and China.

About AstraZeneca

AstraZeneca is a global, innovation-driven biopharmaceutical business that
focuses on the discovery, development and commercialisation of prescription
medicines, primarily for the treatment of diseases in three main therapy areas -
respiratory, inflammation, autoimmune disease (RIA), cardiovascular and
metabolic disease (CVMD) and oncology - as well as infection and neuroscience
diseases. AstraZeneca operates in over 100 countries and its innovative
medicines are used by millions of patients worldwide. For more information
please visit: www.astrazeneca.com

CONTACTS

Media Enquiries
Esra Erkal-Paler        UK/Global            +44 20 7604 8030
Vanessa Rhodes          UK/Global            +44 20 7604 8037
Karen Birmingham        UK/Global            +44 20 7604 8120
Jacob Lund              Sweden               +46 8 553 260 20
Michele Meixell         US                   +1 302 885 2677
Investor Enquiries
UK
Thomas   Kudsk Larsen   Oncology             +44   7818 524185
Eugenia   Litz          RIA                  +44   7884 735627
Nick   Stone            CVMD                 +44   7717 618834
Craig   Marks           Finance              +44   7881 615764
Christer   Gruvris      Consensus Forecasts  +44 7827 836825
US
Lindsey   Trickett      Oncology, ING        +1 240 543 7970
Mitch   Chan            Oncology             +1 240 477 3771
Dial   / Toll-Free                            +1 866 381 7277

Key: RIA - Respiratory, Inflammation and Autoimmunity, CVMD - Cardiovascular and
Metabolic Disease,
ING - Infection, Neuroscience and Gastrointestinal

23 November 2015

-ENDS-